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Abstract
Background: Transcatheter Mitral Valve-in-Valve Implantation (TMViVI) has recently emerged as a novel therapy for
degenerated mitral valve bioprosthesis. Re-operative mitral valve surgery is associated with a substantial risk of mortality and morbidity. The objective of this study was to describe the outcomes of transcatheter mitral valve-in-valve
implantations in our cardiac center.
Methods: Twenty-two patients underwent the valve-in-valve procedure because of bioprosthesis degeneration from
March 2017 to October 2018. Clinical, echocardiographic, procedural details and survival at follow up were assessed.
Results: Eight patients refused re-operative cardiac surgery while others were deemed a high risk for conventional reoperative sternotomy. All patients had TMViVI performed via a trans-septal approach, and the prosthesis was implanted
successfully with immediate hemodynamic improvement in 20 patients. One patient had tamponade (4.55%), two had
permanent pacemaker insertion (9.09%), two patients had a renal impairment (9.09%), and three patients had vascular
complications (13.64%). There was one aborted procedure for the failure to cross the tissue valve with a transcatheter
valve, and one patient was converted to an emergency mitral valve surgery. All patients were discharged in NYHA class
I/II and NYHA class was markedly improved at one-year follow-up (p ¼ 0.002).
Conclusions: Trans-septal mitral valve-in-valve implantation can be performed safely for degenerative mitral valve
bioprosthesis and with favorable early clinical and hemodynamic outcomes.
Keywords: Degenerated mitral bioprosthesis, Transcatheter mitral valve implantation, Trans-septal mitral valve in valve

Introduction

T

ranscatheter Mitral Valve-in-Valve Implantation (TMViVI) has recently emerged as a
novel therapy for degenerated mitral valve bioprosthesis. [1] Reoperative sternotomy for mitral
valve surgery is associated with a substantial risk
of mortality and morbidity. Additionally, the

patients who undergo re-operative mitral valve
replacement are older and more fragile. [2]
Therefore the popularity of TMViVI is increasing
for treating degenerated bioprosthesis in patients
with high surgical risk.
Transcatheter valve-in-valve replacement was
added to the armamentarium of mitral valve intervention; since then, the discussion and the trade-
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offs between mechanical and bioprosthetic valves
are changing. [3] The recent AHA/ACC focused
update of the 2014 AHA/ACC guideline for the
management of patients with valvular disease
deﬁned the role of valve-in-valve as a class IIb
recommendation. [3] valve-in-valve, valve-in-ring,
and valve-in-mitral annular calciﬁcation were previously evaluated with inconsistent results, and
there is fast-growing literature on this subject. [4]
Most of the available publications discussed the
short-term outcomes, while the intermediate and
long-term outcomes remain to be evaluated. Since
TMViVI is increasingly used, we aimed to present
our experience in transcatheter mitral valve-invalve for the management of degenerated mitral
bioprosthesis, describe the patients who had this
procedure, and their outcomes.

Patients and methods

Abbreviations
ACT
AVR
ES II
IRB
LA
LAA
LV
LVOT
NYHA
TEE
TMViVI
TTE

activated clotting time
Aortic valve replacement
EuroScore II
Institutional Review Board
Left atrium
Left atrial appendage
Left ventricle
Left ventricular outﬂow tract
New York Heart Association
Trans-esophageal echocardiography
Transcatheter Mitral Valve-in-Valve
Implantation
Trans-thoracic echocardiography

valve types were suitable for the valve in valve
implantation.

Patient population
Ethical considerations
From March 2017 to September 2018, thirtyethirty
patients were admitted to our tertiary referral cardiac center with a degenerated mitral bioprosthesis.
Eleven patients had re-operative isolated mitral
valve surgery, and 22 patients were assigned to
catheter-based intervention based on the decision of
the interdisciplinary heart team, and all patients
were deemed to be high-risk candidates. Patients
who refused surgery were considered suitable candidates for the transcatheter mitral valve-in-valve
procedure (n ¼ 8). Patient who underwent transcatheter mitral valve in valve had symptomatic severe mitral regurgitation (n ¼ 10; 45%), severe mitral
stenosis (n ¼ 6; 27%) or mixed pathology (n ¼ 6;
27%).
A pre-procedural secure database of patients’
demographics, preoperative risk assessment, and
procedural data were created and included procedure details and operative outcomes. Follow-up
data were collected at 30, 180, and 365 days. Transthoracic echocardiography was performed in all
patients pre- and post-procedure. Patients were
routinely scheduled for clinical follow-up 30 days
after the procedure.
We do not perform transcatheter mitral valve in
valve in patients with infective endocarditis, mitral
valve vegetations and patients with a thick interatrial septum. Patients with valve size less than 25
were considered unﬁt for transcatheter intervention
for the possibility of patient prosthesis mismatch.
Patients with a pre-procedure paravalvular leak can
be managed concomitantly; however, none of our
patients had a concomitant paravalvular leak. All

The nature of valve-in-valve implantation in the
non-aortic position was discussed with each patient
as part of the informed consent process by the
procedure's assigned consultant interventionist. The
study was approved by the Institutional Review
Board (IRB), and the patient's consent to participate
in the study was waived because of the retrospective
nature of the research.
Echocardiography
All valve-in-valve procedures were concluded
with a thorough assessment of valvular hemodynamics and the ﬂow characteristics before, during,
and immediately following valve implantation with
echocardiography. Transthoracic echocardiography
(TTE) was done before the procedure to evaluate the
prosthesis morphology and function as well as for
the routine measurements. Transesophageal echocardiogram (TEE) was the guidance tool throughout
the procedure. Pre-procedural TEE was conducted
to conﬁrm the absence of left atrial appendage
(LAA) thrombus and afﬁrm the ﬁndings of the TTE
as regard to the morphological and functional status
of the bioprosthesis.
Intraprocedural TEE and ﬂuoroscopy were used
in septal puncture guidance. It was crucial to assess
the appropriate positioning of the valve, the mitral
valve gradients, and the absence of a periprosthetic
leak. TEE was pivotal to rule out any encroachment
effect of the prosthesis, particularly on the left
ventricular outﬂow tract (LVOT).

The trans-septal approach in valve-in-valve
implantation
The valve-in-valve implantation procedures
were performed in our hybrid operative room.
Twenty-one patients had the procedure performed
under general anesthesia, and one patient had
moderate sedation. All patients had transesophageal echocardiography (TEE) continuous
guidance. The right femoral vein access was used
to perform the trans-septal puncture. After
securing the Guideright™ J tip (St. Jude Medical,
Inc., St. Paul, MN, USA) long wire into the left
innominate vein, the trans-septal sheath was
introduced over the wire. The trans-septal needle
BRK™ 1 (St. Jude Medical, Inc., St. Paul, MN, USA)
was then introduced into the sheath and kept few
millimeters short of the tip of the sheath. Under
both ﬂuoroscopy and TEE guidance, the sheathneedle assembly was pulled back slowly in a
clockwise rotation to achieve a posterior direction.
At the superior-posterior position, the septum was
punctured, and the sheath was secured into the left
atrium (LA). A ﬁve French diagnostic Judkins right
catheter (JR4) was introduced into the LA via the
trans-septal sheath. A Terumo soft exchange wire
inside the JR4 (Terumo, Somerset, NJ, USA) was
introduced into the left ventricle (LV) via the mitral
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prosthesis, and JR4 was then further introduced
into the LV. The extra stiff Conﬁda™ Brecker
guidewire (Medtronic Inc, Minneapolis, Minnesota, USA) was secured into the LV through the
JR4. After securing the trans-septal sheath into the
LA, heparin was given intravenously to keep activated clotting time (ACT) more than 250 s
throughout the procedure.
A fourteen French (14F) Edward sheath was then
secured in the right femoral vein over the stiff wire.
The septum is dilated using Z-MED-X™ (NuMED
Canada Inc., Cornwall, ON, Canada) 14F balloon to
facilitate the passage of the transcatheter Heart
Valve across the septum. Edwards Sapien 3 Transcatheter Heart Valve (Edwards life sciences, Irvin
California, USA) was used in all patients (Fig. 1).
The transcatheter heart valve was crimped in a
reverse fashion onto the balloon compared with the
same valve used in the aortic position; so that the
outer skirt was directed towards the LA. The valvein-valve mitral app version 2.2 developed by the
technology company UBQO and Dr. Vinayak Bapat
(Retrieved from http://www.ubqo.com/vivmitral),
was used to choose the valve size to be used according to the size of the degenerated mitral bioprosthesis to be treated in every patient. Similar to
Cheung and associates,[5] the transcatheter valve
was placed to slightly overlapping the stent of the

Fig. 1. Trans-septal Approach in mitral valve-in-valve implantation. After right femoral vein access, septal puncture, and dilatation by ballooning
(A), the transcatheter heart valve in a reverse fashion was positioned and deployed in the degenerated bioprosthesis (B; C). Edwards Sapien 3
transcatheter valve successfully implanted on a degenerated mitral bioprosthesis (D).
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Fig. 2. Intraprocedural transesophageal echocardiographic guidance. A. intra-atrial septum tenting B. Trans-septal sheath into the left atrium C.
ballooning the septum D. the degenerative mitral bioprosthesis with immobile leaﬂet E. Competent mitral valve-in-valve F and G. Pre- and postprocedure mitral valve gradients.

degenerated bioprosthesis into the LA for sufﬁcient
anchoring. No ventricular pacing was used at any
stage of the procedure.
Pre-implantation balloon dilatation was performed in 10 patients (45%), and one patient had
post-implantation balloon dilatation. Subsequently,
valve performance was assessed with TEE and
ﬂuoroscopy (Fig. 2).
In the case of concomitant transcatheter aortic valve
implantation, the aortic valve was deployed retrogradely via the transfemoral arterial approach into
the aortic valve before the mitral valve intervention.
Concomitant intervention to the tricuspid valve was
done after transcatheter mitral valve implantation.
After the procedure, all patients with no other
indications for anti-coagulation were started on

warfarin combined with Aspirin for 3 months with
target INR between 2 and 3. This is followed by
lifelong Aspirin only.
Statistical analysis
Continuous data were described as median and
(25th- 75th percentiles) and categorical data as
number and percent. A comparison between the pre
and post-procedural echocardiographic data was
performed using Wilcoxon matched-pairs signedrank test, and pre and post-procedural categorical
variables were compared using the McNemar test.
KaplaneMeier curve was used to present survival
distribution. Stata 14.2 was used to analyze the data
(Stata Corp- College Town- TexaseUSA).

Table 1. Baseline patients' data. Continuous variables are presented as
median (25th- 75th percentiles) and categorical variables as number
(percent). BMI: body mass index; BSA: body surface area; COPD:
chronic obstructive pulmonary disease; LV: left ventricle; LVEDD; left
ventricular end-diastolic diameter; LVESD: left ventricular end-systolic
diameter; PASP: pulmonary artery systolic pressure.
Variable

Total number of
patients (22)

Age (Years)
Female
BMI (Kg/m2)
BSA (m2)
Diabetes mellitus
Hypertension
COPD
Heart Failure in the previous 2 weeks
Chronic kidney disease
Atrial ﬁbrillation
Mitral valve bioprosthesis model
Mosaic
Hancock
Perimount
Epic
Carpentier- Edward (Magna)
LVEDD (mm)
LVESD (mm)
PASP (mmHg)
Indexed LV mass (g/m2)
Ejection fraction (%)

73 (67e78)
16 (72.73%)
29.45 (25.22e33.73)
1.7 (1.6e1.9)
11 (50%)
15 (68.18%)
3 (13.64%)
6 (28.57%)
2 (9.09%)
11 (50%)
6 (27.27%)
1 (4.55%)
9 (40.9%)
3 (13.64%)
1 (4.55%)
45 (41e53)
30 (27e36)
60 (55e75)
96.4 (80.6e121.3)
55 (50e60)

Results
Baseline data
Patients characteristics and co-morbidities are
presented in Table 1. Most patients presented in
NYHA class III/IV (n ¼ 17; 77.27%) One patient had a
history of stroke (4.55%), three patients had a permanent pacemaker (13.64%), two patients had cardiomyopathy (9.09%), and one patient (4.55%) had a
previous percutaneous coronary intervention (PCI).
Six patients had a history of coronary artery bypass
grafting (CABG) (27.27%), and seven patients had
aortic valve replacement (AVR) with a tissue valve
(31.82%). Ten patients had prior tricuspid valve (TV)
intervention (45.45%): ring repair in 5 patients
(22.73%), De Vega repair in 4 patients (18.18%), and
TV replacement with bioprosthetic valves in 3 patients (13.64%). Median creatinine clearance was
67.5 mg/dl (25th- 75th percentiles; 40e78) and hemoglobin was 11.9 mg/dl (25th- 75th percentiles;
10.1e13.4). STS score for mitral valve replacement
was 5.59 (25th- 75th percentiles; 4.4e7.6), and EuroScore II (ES II) was 6.63 (25th- 75th percentiles;
5.5e9.5). All patients had prior mitral valve replacement with a bioprosthetic valve (median size 25;
25th- 75th percentiles: 25e27). Median time from
mitral valve replacement to transcatheter mitral
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valve implantation was 6.33 years (25th- 75th percentiles: 4.35e10.65). Pre-procedural echocardiographic data are shown in Table 1.
Procedural and post-procedural details
All patients had a trans-septal approach to the
mitral valve via the right femoral vein. Twenty-one
patients (95.45%) had general anesthesia, and one
patient had moderate sedation. There was one
aborted procedure for the failure to cross the tissue
valve with a transcatheter valve, and the patient was
enlisted for re-operative mitral valve replacement
(MVR). This patient had Carpentier-Edward
(Magna) valve size 27, and the leaﬂets were fused
and stuck. On the other hand, one patient was
converted to an emergency MVR because the
deployment was to LVOT. Pre-implantation balloon
insufﬂation was used in 10 (45.45%). Edward Sapien
(Edwards life sciences, Irvin California, USA) was
used in all patients (median size 26 mm; 25th- 75th
percentiles: 23e29). One patient (4.5%) required
inotropic support during the procedure, and four
patients had mild MR post-implantation (20%).
Concomitant procedures were performed in 4
patients, 2 had a tricuspid valve in valve implantation, one patient had an aortic valve in valve implantation, and one had transcatheter aortic valve
implantation.
Post-procedure complications and discharge echocardiographic measurements are shown in Table 2. No
patient had a paravalvular leak, device migration, or
thrombosis
post-implantation.
Discharge
Table 2. Post-procedural complications and discharge echocardiographic measurements. Continuous variables are presented as median
(25th- 75th percentiles) and categorical variables as number (percent).
AF: atrial ﬁbrillation; CCU; coronary care unit; LVOT: left ventricular
outﬂow tract; LV: left ventricle; LVEDD; left ventricular end-diastolic
diameter; LVESD: left ventricular end-systolic diameter; PASP: pulmonary artery systolic pressure; PMM: permanent pacemaker.
Variable
New-onset AF
PMM insertion
LVOT obstruction
Perforation and tamponade
Renal impairment and dialysis
Hemorrhagic stroke
Vascular complications
In-hospital death
CCU stay (hours)
Hospital stay (days)
Ejection fraction (%)
LVEDD (mm)
LVESD (mm)
PASP (mmHg)
Indexed LV mass (g/m2)

3 (13.64%)
2 (9.09%)
1 (4.55%)
1 (4.55%)
2 (9.09%)
2 (9.09%)
3 (13.64%)
2 (9.09%)
27.5 (23e92)
14 (6e20)
55 (50e60)
41.5 (31e47)
26 (21.5e31)
50 (45e55)
92.15 (80.25e124.45)
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Table 3. Echocardiographic changes pre and post-procedure. Continuous variables are presented as median (25th- 75th percentiles). MV: mitral valve;
PASP: pulmonary artery systolic pressure.
Ejection fraction (%)
MV peak gradient (mmHg)
MV mean gradient (mmHg)
PASP (mmHg)

Pre-procedure

Post-procedure

p

55 (50e60)
21.1 (18.8e25.2)
8.3 (6e10.9)
60 (55e75)

55 (50e60)
15.7 (13.2e19.6)
6.9 (6e8.2)
50 (45e55)

0.74
0.0002
0.0030
0.0037

echocardiography showed a signiﬁcant decrease in
mean and peak mitral valve pressure gradient and
pulmonary artery systolic pressure (Table 3).
The median follow-up duration was 12.5 months
(25th and 75th percentiles: 4e17). During the followup, mitral valve replacement was performed after
three months for LV pseudoaneurysm in one patient, and one patient had MVR after eight months
for mitral valve infective endocarditis. At one year,
there was a marked improvement in the NYHA
class, and two patients were in class III (p ¼ 0.002).
Seven patients required re-hospitalization after the
procedure (4 of them for cardiac causes) with a
median time to re-hospitalization ﬁve months (25th75th percentiles: 3.5e8.5). Survival at 12 months was
86% (Fig. 3).

Discussion
Re-operative mitral valve replacement surgery is
associated with increased morbidity and mortality,
particularly in elderly and fragile patients. The reported operative mortality can reach 15%. [6,7]
Transcatheter valve-in-valve implantation was
endorsed in the new European Society of Cardiology (ESC)/European Association for CardioThoracic Surgery (EACTS) Guidelines (2017) as an
option for the management of degenerated bioprosthesis in high surgical risk patients and after
multidisciplinary heart team discussion to individualize the approach to each patient. [8] In the annual

Fig. 3. KaplaneMeier survival distribution.

transcatheter valve therapy registry report of The
Society of Thoracic Surgeons/American College of
Cardiology, the patients who had mitral valve-invalve implantation were high risk, with an STS
predicted risk of mortality for mitral valve replacement of 11%. They found 7.2% hospital mortality
and 8.5% 30-day mortality. [9]
All patients included in this study were discussed
by our heart team, which consists of cardiologists
and cardiac surgeons. The patients were assigned to
transcatheter mitral valve-in-valve implantation if
they were either considered high risk for conventional mitral surgery or if they refused it.
We used the trans-septal approach with successful implantation in 90% of the patients. Trans-septal
access is simple and less invasive compared to the
trans-apical approach. It causes no LV damage,
which can happen with the latter approach. [10]
Signiﬁcant bleeding is usually experienced from the
apical cannulation, making the trans-septal
approach a better option. [11]
Yoon and coworkers, [12] in their study about
transcatheter mitral valve implantation for degenerated bioprosthesis enrolled 248 patients who were
deemed high surgical risk based on STS score, and
they concluded that transcatheter mitral valve
replacement provided an acceptable outcome in this
cohort of patients.
The correct sizing of the transcatheter heart valve
is extremely important for a successful procedure,
and multimodal information should be used. These
include TEE, cardiac computerized tomography
scan, and the valve-in-valve app. [13] We used the
valve-in-valve app version 2.2 as our sizing reference after conﬁrming the surgical valve label in the
cardiac surgery document for every speciﬁc patient.
Balloon valvuloplasty was used in 10 patients before
valve-in-valve implantation, and one patient had
difﬁculty in crossing the degenerated valve and was
scheduled for mitral valve surgery.
Immediately after the procedure, the mitral valve
function improved with a signiﬁcant reduction to the
complete disappearance of mitral regurgitation (MR),
and three patients had mild MR. Two patients who
had predominant MS had a signiﬁcant reduction of
the mean gradient across the mitral valve

(8.8 mmHge2 mmHg; 12.3 mmHge5 mmHg) at the
same heart rate indicating the successful treatment of
the MS. No dye was needed in any patients because
we used the radiopaque frame of the surgical prosthesis to deploy the valve. Our results are consistent
with other published series, which showed that mitral
valve-in-valve for degenerated bioprosthesis was
associated with low periprocedural complications
and good long-term outcomes. [14]
In-hospital mortality was reported in 2 patients
(9.09%), and survival at one year was 86%. In a
meta-analysis on mitral valve-in-valve for degenerated bioprostheses, the trans-apical approach was
used in 55% of the patients and hospital mortality
5.7%, and 23.4% at six months. [15]
During the one-year follow-up, there was no reported valve-related complications or structural
degeneration. Clinical status improved, and NYHA
functional class improved immediately and was
signiﬁcantly better after a one-year follow-up. Ye
and associates reported eight years single-center
experience involving 42 cases of Aortic valve-invalve and 31 mitral valve-in-valve and stated that
the procedure could be performed safely with a high
success rate and encouraging midterm clinical
outcome in high surgical risk patients. [16] Additionally, reporting and analyzing the long term data
of this approach in a large cohort of patients is
recommended. [16]
Study strengths and limitations
The major limitation of the study is the retrospective nature with its inherited referral and selection biases. Another limitation is the small
patients' number, which is considered acceptable for
this newly introduced technique. Finally, there is a
lack of comparison group with surgical mitral valve
replacement; however, most of our patients were
included because they were deemed unﬁt for surgical interventions. Of particular interest, this
retrospective study reported unique techniques and
work-up. The procedures were done in a hybrid
operative room. No CT scan was needed for periprocedural work-up. The approach was trans-septal
in all patients, and neither pacing nor contrast was
used.

Conclusion
Trans-septal mitral valve-in-valve implantation
can be performed safely for degenerative mitral
valve bioprosthesis and with favorable clinical and
hemodynamic early outcomes. It can offer a viable
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option in patients with high surgical risk and or in
patients who reject conventional surgery.
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